Krystal Biotech (NASDAQ:KRYS) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Krystal Biotech (NASDAQ:KRYS) in a report issued on Wednesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $245.00 target price on the stock.

Other equities analysts also recently issued research reports about the stock. Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Chardan Capital lifted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $220.00.

Krystal Biotech Trading Up 0.6 %

KRYS opened at $179.93 on Wednesday. The company has a market cap of $5.18 billion, a price-to-earnings ratio of 60.18 and a beta of 0.87. The company’s 50 day moving average is $161.18 and its 200 day moving average is $174.74. Krystal Biotech has a 12-month low of $141.72 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm’s revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.30 earnings per share. As a group, analysts predict that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Krystal Biotech during the fourth quarter valued at $3,634,000. GF Fund Management CO. LTD. purchased a new stake in shares of Krystal Biotech during the fourth quarter valued at $95,000. Palisades Investment Partners LLC boosted its stake in shares of Krystal Biotech by 9.3% during the fourth quarter. Palisades Investment Partners LLC now owns 40,479 shares of the company’s stock valued at $6,341,000 after purchasing an additional 3,436 shares during the period. Woodline Partners LP boosted its stake in shares of Krystal Biotech by 23.0% during the fourth quarter. Woodline Partners LP now owns 221,102 shares of the company’s stock valued at $34,638,000 after purchasing an additional 41,287 shares during the period. Finally, Soleus Capital Management L.P. boosted its stake in shares of Krystal Biotech by 65.2% during the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock valued at $56,144,000 after purchasing an additional 141,400 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).